Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

  • STATUS
    Recruiting
  • End date
    Dec 9, 2022
  • participants needed
    328
  • sponsor
    Xiamen LP Pharmaceutical Co., Ltd
Updated on 9 June 2022

Summary

The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.

Description

This is a phase 3 randomized, double-blind, parallel group study designed to evaluate the efficacy and safety of palonosetron HCL buccal film versus IV palonosetron for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy (MEC).

Subjects are randomized into two treatment groups, one with the experimental study drug palonosetron in buccal film, the other one with the control treatment using Palonosetron hydrochloride IV injection. Palonosetron PK will be assessed in a subgroup of each treatment group (two sample points, 10% of subjects).

Details
Condition Chemotherapy-induced Nausea and Vomiting
Treatment Palonosetron HCl Buccal Film 0.5 mg, IV Palonosetron 0.25 mg
Clinical Study IdentifierNCT05199818
SponsorXiamen LP Pharmaceutical Co., Ltd
Last Modified on9 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female, at least 18-years of age
Provide written informed consent
Chemotherapy naïve subject with histologically or cytologically confirmed malignant disease; or chemotherapy non-naïve subject with histologically proven diagnosis of cancer
Karnofsky index ≥ 50
Be scheduled to receive MEC to be administered on Day 1

Exclusion Criteria

Unable to understand or cooperate with study procedure;
Received any investigational drug 30 days prior to study entry;
Used any drug with anti-emetic efficacy 24 hours prior to treatment and during the study;
Enrollment in a previous study with palonosetron;
Seizure disorder requiring anticonvulsant medication
Experienced any vomiting, retching, or NCI Common Toxicity Criteria grade 2 or 3 nausea in the 24 hours preceding chemotherapy;
Ongoing vomiting from any organic etiology;
Experienced nausea (moderate to severe or vomiting following any previous chemotherapy);
Scheduled to receive moderately or highly-emetogenic chemotherapy or radiotherapy during the study;
Known contraindication to 5-HT3 antagonist or dexamethasone;
Lactating female
Scheduled to receive bone marrow or stem cell transplant during study
Symptomatic primary or metastatic CNS malignancy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note